ArticleBiochemistry and biophysics reports2026
Comprehensive analysis of mutational signatures and corresponding driver genes in cervical cancer from Xinjiang.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the mutational characteristics of cervical cancer in Xinjiang and their relationships with tumor driver genes and affected signaling pathways. Methods: Twenty-nine pairs of cervical cancer tissues and matched peripheral blood samples were subjected to Whole Exome Sequencing. Somatic mutation sites and tumor mutational burden were identified, and core mutational signatures using non-negative matrix factorization (NMF). Driver genes were screened, and pathway enrichment analysis was performed to clarify the associations between core oncogenic pathways and driver genes. Results: A total of 10,076 nonsynonymous mutations in the coding region were identified. High-frequency mutated genes included members of the MUC family, HRNR, and NBPF1. Single-base substitutions were dominated by C > T (38.63%). Three core mutational signatures were identified: Signature A (undefined), Signature B (APOBEC-mediated deamination), and Signature C (endogenous damage/mismatch repair deficiency). Samples were divided into two groups based on these signatures: Group 1 (high C > G/C > T mutations) and Group 2 (high C > T mutations). Eleven driver genes were identified; among SLC24A1 was a driver gene in both the overall samples and subgroups, suggesting it is a key driver gene in cervical cancer. Gene mutations were mainly enriched in five pathways: NOTCH, RTK-RAS, WNT, Hippo and PI3K. Subgroup pathway signatures consistent with the overall cohort, differing only in mutation frequencies. Conclusion: This study clarified cervical cancer genomic heterogeneity, revealed core mechanisms (APOBEC activation and endogenous DNA damage), and confirmed SLC24A1 as key driver gene. It provides important genomic evidence for elucidating the pathogenesis of cervical cancer and exploring potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.